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ABSTRACT
Stressful and traumatic life events (STLEs) are common among HIV-infected individuals and may
affect health behaviors such as adherence to antiretroviral (ARV) therapy, with important
implications for treatment outcomes. We examined the association between STLEs and ARV
adherence among 289 US-based participants enrolled between 7/1/2010 and 9/1/2013 in a study
of depression treatment for HIV-infected patients. Participants received monthly telephone calls
to assess STLEs and pill count-based ARV adherence. Inverse probability of observation
weighting was combined with multiple imputation to address missing data. Participants were
mostly male (71%) and black (63%), with a median age of 45 years. Median monthly adherence
was 96% (interquartile range (IQR): 85–100%). Participants experienced a mean of 2.48 STLEs
(range: 0–14) in the previous month. The presence of ≥2 STLEs was associated with a mean
change in adherence of −3.67% (95% confidence interval (CI): −7.12%, −0.21%) and decreased
likelihood of achieving ≥95% adherence (risk ratio (95% CI) = 0.82 (0.71, 0.95)). For each
additional STLE, the mean adherence change was −0.90% (95% CI: −1.79%, 0.00%). STLEs were
associated with poorer ARV adherence, including decreased likelihood of adhering to ≥95% of
ARV doses. This level of adherence has a critical role in regimen effectiveness and prevention of
resistance.
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Persons living with HIV/AIDS (PLWHA) face a number
of challenges related to their HIV infection, including
life-long use of antiretroviral (ARV) medications,
HIV-related stigma, and opportunistic infections.
Depression is also common, affecting upwards of 20%
of PLWHA in the USA (Bing et al., 2001; Burack et al.,
1993; Ickovics et al., 2001; Kilbourne, Justice, Rabeneck,
Rodriguez-Barradas, & Weissman, 2001; Lyketsos et al.,
1993; Lyketsos, Hutton, Fishman, Schwartz, & Treisman,
1996), in comparison to 12%–13% of the general popu-
lation (Kessler et al., 2003). More attention has been
paid recently to stressful and traumatic life events
(STLEs) among PLWHA, which are common in this
population (Whetten et al., 2006; Wong, Sarkisian,
Davis, Kinsler, & Cunningham, 2007), and may have
important implications for psychological, behavioral,
and other outcomes. STLEs include moderately or
severely stressful or traumatic events such as death or
illness of family or friends; difficulties with relationships,
finances, or employment; legal trouble; threats to safety;
housing instability; and physical or sexual assault. STLEs
are experienced more often by PLWHA than by the gen-
eral population, in part due to the predominance of HIV
infection among populations experiencing economic and
other difficulties that are often related to such events
(Mugavero et al., 2009).
Previous studies of STLEs have documented their
high prevalence and association with negative clinical
and behavioral outcomes. In the Coping with HIV/
AIDS in the Southeast (CHASE) study, HIV-infected
participants reported medians of nine incident stressful
events and three incident severely stressful events over
two years (Mugavero et al., 2009). Increasing numbers
specifically of traumatic events were associated with
higher rates of unprotected sex, worse medication adher-
ence, increased emergency department use and hospital-
ization, accelerated HIV disease progression, and
increased mortality rates (Leserman et al., 2007;
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Mugavero et al., 2009; Pence, Mugavero, et al., 2012). In a
separate, cross-sectional study of HIV-uninfected young
men who have sex with men, recent financial- and
health-related stressful events were associated with
increased risk of substance use, and recent health- and
partner-related stressors were associated with sexual
risk-taking (Wong, Kipke, Weiss, & McDavitt, 2010).
One important HIV-related outcome that STLEs may
affect is adherence to ARV medication. STLEs can cause
disruptions to routines, and for PLWHA, such disrup-
tions may result in decreased ARV adherence. Adequate
ARV adherence is necessary to achieve viral suppression,
maintain health, and avoid developing drug resistance
(Bangsberg, 2006; Bangsberg, Moss, & Deeks, 2004;
Maggiolo et al., 2007; Shuter, Sarlo, Kanmaz, Rode, &
Zingman, 2007). Two prior studies examined the associ-
ation between STLEs and self-reported ARV adherence
and found that increased frequency and greater severity
of events were associated with poorer adherence (Leser-
man, Ironson, O’Cleirigh, Fordiani, & Balbin, 2008;
Mugavero et al., 2009). Both studies relied on self-
reported ARV adherence and long recall periods for
STLEs, which may have affected exposure and outcome
measurement accuracy.
The current study examined the longitudinal associ-
ation between STLEs and ARV adherence, measured
monthly by pill counts, among adults in the Southeastern
USA with HIV and depression. Unannounced, tele-
phone-based pill counts have been shown to provide
valid, accurate measures of adherence (Kalichman
et al., 2007), and are more sensitive than self-report to
adherence changes over time (Lee et al., 2007). Pill
counts may, therefore, allow for a more accurate assess-
ment of the relationship between STLEs and ARV adher-
ence. Likewise, recent STLEs may be more strongly
related to current ARV adherence than STLEs measured
over longer recall periods. We hypothesized that higher
numbers and severity of STLEs would be associated
with poorer ARV adherence, and that improved
measurements of both STLEs and adherence would




Data for this study came from the Strategies to Link
Antidepressant and Antiretroviral Management at Duke
University, the University of Alabama-Birmingham,
Northern Outreach Clinic (Henderson, NC), and the Uni-
versity of North Carolina-Chapel Hill (SLAM DUNC)
Study, a randomized, controlled trial testing the effect of
evidence-based decision support for depression treatment
on ARV adherence, which has been described previously
(Pence, Gaynes, et al., 2012). The study population com-
prises adult (age 18–65 years) HIV-infected patients
with depression attending infectious disease clinics at the
study sites. Participants enrolled between 1 July 2011
and 30 September 2013were eligible for the current analy-
sis; data on STLEs were collected during this period. Par-
ticipants were followed for up to one year following
enrollment, receiving up to 12 monthly pill count calls.
The number of calls completed depended on attrition
and timing of enrollment relevant to collection of STLE
data and the end of the study. Study procedures were
approved by the Institutional Review Boards at the Uni-
versity of North Carolina at Chapel Hill, Duke University,
and the University of Alabama at Birmingham.
Measures
Stressful and traumatic life events
STLEs were assessed during monthly telephone calls
with participants using the Life Events Survey (LES)
(Leserman et al., 2008; Sarason, Johnson, & Siegel,
1978), modified to include those events considered mod-
erately or severely stressful or traumatic based on prior
research (Leserman et al., 2002, 2005). Participants
were asked whether they had experienced any of 46
events, from within nine categories, during the prior
month. STLE categories were: (1) romantic relationship
changes; (2) estrangement from family; (3) death or
serious illness of family member or close friend; (4)
major illness, injury, or hospitalization; (5) employment
difficulties; (6) financial difficulties; (7) legal difficulties;
(8) life transitions; and (9) safety concerns (e.g., physical
attacks, feeling unsafe). The total number of STLEs
reported at each time point (monthly) was summed for
each participant and coded discretely. The exposure
was also dichotomized, to indicate experiencing at least
the study population median number of STLEs vs. less
than the median number, during the month prior.
Additionally, the most potentially severe STLEs (div-
orce/separation, death/illness of immediate family mem-
ber, major financial problems, time in jail, and sexual
and/or physical assault) were combined, based on prior
work (Mugavero et al., 2009), to create a second discre-
tely-coded variable. The severe-only total was dichoto-
mized to indicate one or more severe STLEs vs. zero
during the past month.
Antiretroviral adherence
ARVadherencewasmeasured bymonthly, unannounced,
telephone-based pill counts and recorded as a continuous
percentage. Adherence was calculated as the observed
number of pills taken since the last count divided by the
expected number of pills taken since the last count. The
observed number of pills taken was the number of pills
present at the current count, subtracted from the number
present during the previous count, after accounting for
pills gained (e.g., dispensed) and lost (e.g., thrown away)
in the interim. The expected number of pills taken was
the prescribed daily number of pills, multiplied by the
number of days since the previous count. Both the
observed and expected number of pills were summed
across all ARV medications prior to dividing. Values of
adherence <0% (n = 20) or >200% (n = 1) were discarded
as outside the range of plausibility.
Secondary analyses explored (1) dichotomous coding
of “adequate” (≥95%) vs. “inadequate” (<95%) adher-
ence (Lima et al., 2009, 2008), and (2) differences
between pill count-based and self-reported adherence.
Self-reported adherence was measured at baseline (in-
person) and every three months thereafter (by tele-
phone) during structured research interviews, with the
following questions: (1) “Over the past month, how
much of the time have you taken all of your HIV/
AIDS medications?” and (2) “Over the past month,
how much of the time have you missed or skipped taking
your HIV/AIDS medications?” Responses, ranging from
0%to 100%, were averaged (after reverse-coding the
second question) to get a measure ranging from 0% to
100%. As self-reported adherence was measured every
three months, while STLEs were measured every
month, the average number of STLEs was calculated
for each three-month time period. Self-reported adher-
ence was also dichotomized at 95%, as above.
Additional covariates
Covariates used in the analysis were sex, age, depressive
severity, HIV care self-efficacy, stress coping style, HIV-
related physical symptoms,HIV status disclosure, employ-
ment status, and drug and/or alcohol abuse. Sex and age
were assessed at study enrollment. Depressive severity,
HIV care self-efficacy, stress coping style, HIV-related
physical symptoms, HIV status disclosure, and employ-
ment status were measured at enrollment and every three
months thereafter. Depressive severity was measured
with the Hamilton Rating Scale for Depression (HAM-
D) (Hamilton, 1960, 1980; Zimmerman, Chelminski, &
Posternak, 2004), and coded discreetly (range: 0–50)
(Hamilton, 1960). HIV-related self-efficacy was measured
using the managing depression/mood, managing symp-
toms, communicating with health care provider, getting
support/help, and managing fatigue subscales of the HIV
Self-Efficacy questionnaire (Shively, Smith, Bormann, &
Gifford, 2002). Stress coping style was assessed with the
Brief COPE instrument (Carver, 1997; Carver, Scheier, &
Weintraub, 1989), and physical symptoms were measured
using the HIV Symptom Inventory (Bing et al., 2001). Dis-
closure of HIV status to (1) close friends/family and (2)
everyday acquaintances was measured separately with
four-point Likert scales (“All,” “Most,” “Some,” or
“None”) and was included as ordinal variables. Employ-
ment was dichotomized to indicate employed vs. not.
Any abuse or dependence of drugs and/or alcohol was
assessed at enrollment and at six- and twelve-month fol-
low-up interviews with the alcohol/substance dependence
and abuse sections of the Mini International Neuropsy-
chiatric Interview (Lecrubier et al., 1997).
Statistical analysis
The main exposure-outcome association was assessed
using a linear model with robust variance to account
for repeated observations on participants, yielding an
estimate of the mean difference in past-month percent
adherence. To address missing covariate values among
completed contacts, multiple imputation by chained
equations (MICE) was employed for all variables
included in the analysis (White, Royston, & Wood,
2011). Ten cycles of imputation were carried out per
imputed dataset; 50 datasets were imputed and analyzed.
To address potential selection bias arising from uncom-
pleted contacts, inverse probability of observation
weights (IPOWs) were calculated for the inverse prob-
ability of completing a given contact conditional on pre-
dictors of contact completion, using a logistic model
(Moodie, Delaney, Lefebvre, & Platt, 2008; Seaman,
White, Copas, & Li, 2012). Baseline and time-updated
variables found to be statistically significantly associated
(at alpha = 0.05) with completion in bivariable analyses
were included in the model. The IPOWs were stabilized
by the marginal probability of contact completion and
used to weight the final exposure-outcome model.
In analyses with dichotomous coding of the ARV
adherence outcome, a Poisson model with robust var-
iance was used instead of a linear model (and in place
of a log-binomial model due to model convergence issues
(Yelland, Salter, & Ryan, 2011)), to yield an estimate of
the risk ratio (RR) for ≥95% adherence. All other ana-
lyses followed the approach described above.
Results
Study population
Two-hundred eighty-nine participants enrolled in the
SLAM DUNC study while STLEs were being measured.
The majority of the study sample (71%) was male, black
(63%), non-Hispanic (96%), and single (78%). Themedian
(interquartile range [IQR]) agewas 45 (38–51), andpartici-
pants reported contracting HIV, on average, 11 years prior
to study enrollment. Eighty-five percent of participants
had at least a high school-level education and 26% were
employed at enrollment. Self-reported past-month ARV
adherence was high at enrollment, with a median (IQR)
of 98% (85–100%) adherence (Table 1).
Participants completed, on average, five monthly tele-
phone interviews (IQR: 1–8); the number of interviews
completed ranged from zero to 12. Of the total possible
2634 monthly interviews, 1412 (54%) were completed
and included in analyses. Among completed contacts,
3373 STLEs were reported, for a mean of 2.48 events
per month; the number of STLEs experienced in a
month ranged from 0 to 14, and the median (IQR) was
2 (1–4). Six hundred seventy-eight severe STLEs were
reported, or 0.50 events per month. Financial difficulties
were most commonly reported, with 1.24 events/month,
followed by illness/injury/hospitalization of the partici-
pant (0.31 events/months) and death/serious illness of
family member/friend (0.25 events/month). Legal trou-
bles were reported least often (0.04 events/month)
(Table 2). Across all contacts, pill count-measured
median (IQR) ARV adherence was 96% (83%–100%).
Missing data
Among completed contacts, multiple imputation was
used to impute missing baseline values for 0.4% of
employment data, 4% viral load, 5% CD4 count, 2%
self-efficacy, and 0.5% SF12 mental functioning score.
There was more substantial missing data for post-base-
line variables. Pill count-measured ARV adherence was
imputed in 15% of observations, employment status in
14%, and HIV status disclosure in 74%. For drug/alcohol
abuse, coping style, self-efficacy, and HIV symptoms,
values were imputed in 11% of observations.
In calculating the IPOWs, baseline predictors of com-
pleting interviews that were statistically significant at
alpha = 0.05 were age, employment, viral load, CD4
count, self-efficacy, and SF12 mental functioning score.
A time-updated variable indicating whether the previous
month’s pill count was completed was also included in
the weighting model. The IPOWs had a mean (standard
deviation) of 1.06 (0.50), and ranged from 0.58 to 5.35.
These weights were applied to the 1412 completed obser-
vations, to account for the 46% of contacts that were not
completed.
Primary outcomes
A greater number of past-month STLEs was associated
with poorer past-month ARV adherence, after adjusting
for confounding by drug/alcohol abuse, coping style,
self-efficacy, employment, HIV symptoms, age, gender,
and HIV status disclosure. One additional STLE experi-
enced was associated with a mean difference (95% confi-
dence interval (CI)) in ARV adherence of −0.99%
(−1.89%, −0.09%), indicating that for each additional
STLE, mean adherence decreased by nearly one percen-
tage point (Table 3). A stronger association was observed
when comparing participants with at least the median
number of STLEs (2) to those with less than the median
(mean difference =−3.67%, 95% CI =−7.12%, −0.21%).
When limited to the most potentially severe STLEs, each
Table 1. Study sample characteristics, Southeastern USA, 2010–
2013 (n = 289).
















Less than HS grad 40 (14)
High school grad 110 (38)
More than high school 136 (47)
Monthly household income ($) 1000 (674–1752) 18
Log-10 income ($) 3 (2.83–3.24)
Currently employed 76 (26) 3
Years since HIV diagnosis 11 (4–17) 11
Baseline log10-viral load 1.67 (1.59–2.31) 11
Baseline viral load 50+ 90 (32)
Baseline CD4 count 539 (326–789) 14
Baseline depression score 21 (15–25) 36
Baseline self-reported adherence 98 (85–100) 26







Total # STLEs 2.48 29.76
Financial difficulties 1.24 14.88
Major illness, injury, or
hospitalization
0.31 3.72
Death/illness of family member/
friend
0.25 3.00
Employment difficulties 0.24 2.88
Safety concerns 0.12 1.44
Romantic relationship changes 0.11 1.32
Estrangement from family 0.10 1.20
Life transitions 0.08 0.96
Legal difficulties 0.04 0.48
Total # severe STLEsa 0.50 6.00
Note: STLEs = Stressful and traumatic life events.
aIncludes: divorce/separation, death/illness of immediate family member,
major financial problems, time in jail, and sexual and physical assault.
additional event was associated with a more extreme
mean difference of −2.43%; however, the 95% CI
(−5.16%, 0.30%) spanned the null value of no difference.
Experiencing any severe STLE vs. none was associated
with a mean adherence difference (95% CI) of −3.03%
(−6.41%, 0.35%). While these associations were modest
in magnitude, they were relatively precisely estimated.
Secondary outcomes
When adherence was dichotomized, each additional
past-month STLE was associated with decreased likeli-
hood of ≥95% adherence in the past month, both overall
(risk ratio (RR) = 0.95, 95% CI = 0.90, 0.99) and for
severe STLEs (RR = 0.84, 95% CI = 0.74, 0.96). The
decreases in likelihood of adherence were more marked
for participants experiencing at least the median number
vs. less than the median number of overall STLEs (RR =
0.82, 95% CI = 0.71, 0.95) and any severe STLE vs. none
(RR = 0.80, 95% CI = 0.69, 0.94) (Table 3). The crude
proportion of observations in which ≥95% adherence
was achieved decreased with increasing number of
STLEs (zero, one, two or more), both for overall and
severe STLEs (Figure 1).
Estimates of association between STLEs and self-
reported ARV adherence were similar in direction and
precision but attenuated compared to pill count-
measured adherence (Table 3). All estimates using self-
reported adherence were closer to the null than the esti-
mates obtained using pill count-based adherence, except
that of the mean difference in ARV adherence when
comparing any severe STLE vs. none.
Discussion
In our study population, representing HIV-infected
patients with depression in the Southeastern USA, a
higher number of STLEs was associated with poorer
ARV adherence, and in particular, lower likelihood of
achieving or maintaining ≥95% adherence. Participants
experiencing at least the median number of STLEs in a
given month had 18% lower likelihood of ≥95%
adherence in that same month, compared to those
experiencing less than the median number. The associ-
ation between STLEs and reduced adherence was similar
when limited to the most severe STLEs.
STLEs were common, with participants reporting, on
average, more than two events per month during follow-
up of up to 12 months; number of events reported
per month ranged from zero to 14 (median (IQR): 2
Table 3. Associations between STLEs and ARV adherence, pill count-based and self-reported, Southeastern USA, 2010–2013.
Pill count-based adherence Self-reported adherence
Mean % adherence






Per 1-unit increase in number −0.99% (−1.89%, −0.09%) 0.95 (0.90, 0.99) −0.63% (−1.61%, 0.35%) 0.98 (0.94, 1.02)
≥2 vs. <2a −3.67% (−7.12%, −0.21%) 0.82 (0.71, 0.95) −1.63% (−5.16%, 1.91%) 0.91 (0.79, 1.05)
Severe STLEs
Per 1-unit increase in number −2.43% (−5.16%, 0.30%) 0.84 (0.74, 0.96) −1.99% (−5.50%, 1.52%) 0.89 (0.77, 1.04)
Any vs. none −3.03% (−6.41%, 0.35%) 0.80 (0.69, 0.94) −3.45 (−6.33, −0.58) 0.84 (0.74, 0.96)
Note: STLEs = Stressful and traumatic life events; ARV = antiretroviral; RR = risk ratio; CI = confidence interval.
a2 = population median monthly number of STLEs.
Figure 1. (a) Proportion with ≥95% ARV Adherence by Number
of STLEs, Southeastern USA, 2010–2013. ARV = antiretroviral,
STLE = stressful or traumatic life event. (b) Proportion with
≥95% ARV adherence by number of severe STLEs. ARV = antire-
troviral, STLE = stressful or traumatic life event.
(1–4)). This high burden of STLEs, similar to that found
in other studies (Leserman et al., 2008; Mugavero et al.,
2009), emphasizes their potential impact on ARV adher-
ence. The relatively modest difference in mean adher-
ence of roughly 1% associated with one additional
STLE implies that an individual experiencing ten
STLEs in a given month could be expected to have
10% lower adherence than an individual experiencing
no STLEs. Also, each additional STLE was associated
with a 5% reduction in the likelihood of ≥95% adher-
ence, and each additional severe STLE was associated
with a 16% reduction. These results suggest that while
the impact of STLEs on continuously measured adher-
ence may be modest, it may be sufficient to reduce adher-
ence below a critical threshold required for regimen
effectiveness and prevention of resistance (Lima et al.,
2009, 2008). The mean differences in adherence and
the reductions in likelihood of ≥95% adherence were
even more pronounced when comparing at least the
median number of STLEs to less than the median, or
any severe STLE vs. none.
Our results add to the existing evidence that ongoing
STLEs may interfere with ARV adherence among
PLWHA. Prior studies have demonstrated this associ-
ation, but have exclusively used self-report to measure
adherence, and long recall periods for STLEs (Leserman
et al., 2008; Mugavero et al., 2009). This is the first study
showing the association between STLEs measured
monthly over time and pill count-based ARV adherence.
Pill counts have been shown to be more sensitive to
changes in adherence over time than self-reported
measures (Lee et al., 2007), and the measurement of
both STLEs and adherence at the same point in time
over short recall periods allowed us to capture more
proximal associations of STLEs with adherence.
We found an attenuation of estimates of association
when ARV adherence was measured by self-report, com-
pared to pill counts. This might be due in part to reduced
variability of the measurement, as self-reported adher-
ence tends to be skewed upwards; however, it is likely
also due to the improved accuracy of using the more
objective measure of unnannouned pill counts. Tele-
phone-based pill counts have been shown to be as accu-
rate as researcher-performed pill counts (Kalichman
et al., 2007).
Previous studies have also used dichotomous out-
comes to indicate adherent vs. non-adherent, based on
report of missing ARV doses. The 5% reduction in risk
of ≥95% adherence in our study is lower than both the
10% increase in non-adherence (OR = 1.10, 95% CI =
1.04, 1.16) in one study assessing missed doses over the
past seven days (Mugavero et al., 2009), and the 36%
increase in non-adherence (OR = 1.36, 95% CI = 1.13,
1.63) in a study using missed doses in the prior two
weeks as the outcome (Leserman et al., 2008). The use
of risk ratios instead of odds ratios in those studies
may account for some of the difference. In our study
there was an 11% reduction in odds of ≥95% adherence
(data not shown). Our continuous pill count measure
allowed us to additionally assess differences in adherence
not tied to a somewhat arbitrary adherent/non-adherent
cut-point.
Strengths of this study include the continuous pill
count measure of adherence, monthly assessments of
both adherence and STLEs, and the availability of a com-
prehensive set of potential confounders for inclusion in
multivariable models. One important limitation was
the low retention rate during follow-up and the resulting
large amount of missing data. Rather than conduct a
complete-case analysis, we used a combination of mul-
tiple imputation and inverse probability of observation
weighting, based on observed predictors of missingness,
to address the potential for selection bias arising from
these missing data. We cannot exclude the possibility,
however, that missingness could also be a function of
unobserved characteristics, and in particular could be
associated both with higher numbers of STLEs and
with lower adherence. If this were the case, the present
analysis would likely have underestimated the actual
association of STLEs with poor adherence, but overesti-
mation is possible as well. There is also the possibility of
misspecification of the weighting model, the imputation
model, or both.
Interventions should be targeted to increase provider
awareness of STLEs, and to improve patient coping skills
to mitigate negative effects of STLEs, in order to improve
ARV adherence. One study found that participants
receiving a quality-improvement intervention, aimed at
increasing the proportion of patients receiving appropri-
ate depression treatment, experienced fewer STLEs than
those in usual care (Sherbourne et al., 2008). Other
studies found that expressive writing about STLEs
being experienced was associated with greater cognitive
engagement, fewer days of activity restriction, and
improved health status (Andersson & Conley, 2013;
Smyth, Stone, Hurewitz, & Kaell, 1999). Other such
interventions, focused on reducing the incidence of
and/or developing skills to cope with STLEs, could be
developed and potentially integrated with direct ARV
adherence support strategies.
STLEs are common and potentially impactful,
especially among persons managing both medical and
mental health diagnoses. While some STLEs are una-
voidable (e.g., death/illness), others (e.g., relationship
problems, employment issues) might be mitigated
through management of depressive symptoms and/or
working with outside help, such as a social worker. In
either case, raising awareness of the frequency and
impact of STLEs among HIV providers, and developing
interventions to prevent or alleviate their negative
impacts could help in maximizing the clinical benefits
of HIV treatment.
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